Common Stock, par value $0.0001 per share
- Symbol
- TRXB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
TRex Bio, Inc.
TRXBNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 13, 2026, TRex Bio, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Press release in this filing
TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights →Company context
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair. Leveraging our Deep Biology drug discovery and design platform, we integrate tissue-level insights into human biology and Treg function to identify and characterize novel targets and approaches for therapeutic intervention. Our tissue-first conviction and unique insights in Treg biology are the foundation of our pipeline of therapeutic candidates aimed at restoring immune balance and promoting tissue repair for more durable disease control.
Current securities
Recent company filings
Registered securities in this filing
TRex Bio, Inc. · 8-K · Filed 2026-11-13
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On November 13, 2026, TRex Bio, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights • Positive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027 • TRB-071 advancing through IND-enabling studies, with Phase 1 trial initiation expected in the first half of 2027 • Completed a $133.5 million initial public offering in October 2026, extending expected cash runway into the second half of 2029 SOUTH SAN FRANCISCO, Calif., November 13, 2026 -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today reported financial results for the third quarter ended September 30, 2026, and provided recent business highlights and anticipated development milestones. “Our approach begins with understanding how regulatory T cells function in human tissues and using those insights to develop medicines intended to address the underlying immune dysfunction in disease,” said Johnston Erwin, Chief Executive Officer of TRexBio. “The positive Phase 1a results for TRB-061 demonstrated selective a…
Open exhibit ↗